Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OsteoBor is a boron-based dietary supplement and nutraceutical primarily used for the prevention and management of osteoporosis, particularly in postmenopausal women. Boron, as a trace mineral, plays a critical role in bone health by modulating the metabolism of essential minerals such as calcium and magnesium, and by influencing the activity of vitamin D and steroid hormones like estrogen. It is often marketed as a combination product, most notably **Osteobor Forte**, which includes additional bone-supporting ingredients such as calcium, magnesium, zinc, and vitamin D3. Clinical research, including trials in Iran, has investigated its efficacy in improving bone mineral density (BMD) and reducing fracture risk as a complementary or alternative therapy to conventional pharmaceutical treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OsteoBor.